{"entity":{"id":"esmo-open","kind":"journal","name":"ESMO Open","aka":["ESMO Open","src-esmo-open"],"tldr":"ESMO's fully open-access journal: trials, real-world studies, ESMO position papers and the Living Guidelines updates, all free to read.","summary":"Gold open access under Creative Commons licences. Publishes phase 2 trials and secondary analyses, real-world evidence, health-economics and access studies, and ESMO's own consensus and position statements. Increasingly the venue for the ESMO Living Guidelines and the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) updates.","asOf":"2026-09-09","links":[{"label":"ESMO","url":"https://www.esmo.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: ESMO open-access journal for trials, real-world data and guidelines. Access: Open access (CC BY / CC BY-NC-ND)."],"publisher":"Elsevier","url":"https://www.esmoopen.com","issn":"2059-7029","scope":"clinical oncology","access":"open-access","founded":2016,"matchNames":["ESMO Open"],"society":"European Society for Medical Oncology"},"route":"/journals/esmo-open/","neighbours":{"institution":[{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"}],"person":[{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/"},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/"}],"paper":[{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/"},{"id":"paper-ehe-consensus-stacchiotti-esmo-open-2021","kind":"paper","name":"Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","route":"/key-papers/paper-ehe-consensus-stacchiotti-esmo-open-2021/"},{"id":"paper-powell-esmo-open","kind":"paper","name":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","route":"/key-papers/paper-powell-esmo-open/"},{"id":"paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021","kind":"paper","name":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021/"},{"id":"paper-van-herpen-esmo-open","kind":"paper","name":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-van-herpen-esmo-open/"},{"id":"paper-tropion-breast01-china-cohort-esmo-open-2026","kind":"paper","name":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","route":"/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/"}]}}